结核潜伏感染动物模型的研究进展

结核潜伏感染(latent tuberculosis infection, LTBI)是机体对结核分枝杆菌抗原持续性免疫反应的状态,既无活动性结核病临床症状,也无结核病影像学表现。LTBI激活是新发结核病的主要来源之一。LTBI动物模型的建立是研究结核的潜伏感染和复发机制,开发诊断试剂,评估抗结核新药、新疫苗的有效性、安全性的基础。建立稳定、成本低、易推广、潜伏期时长适中、复发起点和复发水平变异小的LTBI动物模型,是其未来研究发展的方向。本文就LTBI动物模型的研究进展进行综述,期望为结核病防治工作者提供参考资料。     

结核分枝杆菌Rv2626c诱导的细胞免疫应答特性

全球有近1/4的人感染结核分枝杆菌(Mycobacterium tuberculosis,M.tb)并长期处于潜伏感染状态。Rv2626c是结核分枝杆菌受DosR调控的重要潜伏感染相关蛋白。本研究对Rv2626c蛋白进行了原核表达和纯化,并以RAW264.7细胞和小鼠为感染模型,对其免疫生物学特性进行了分析。SDS-PAGE及Western blotting鉴定结果表明,Rv2626c-His融合蛋白主要以可溶形式表达,能与兔抗H37Rv多抗血清发生特异性免疫反应。此外,本研究发现Rv2626c蛋白能结合到巨噬细胞RAW 264.7表面并上调细胞NO的生成;显著诱导促炎细胞因子IFN-γ、TNF-α、IL-6和MCP-1的产生;并能诱导小鼠产生更强的Th1免疫应答。上述研究有利于揭示结核分枝杆菌的致病机制,为新型结核病疫苗的研制奠定了理论基础。     

耐药结核分枝杆菌感染动物模型所用菌株的筛选

本研究通过小鼠体内实验检测我国部分地区结核分枝杆菌耐药菌株的毒力,以筛选耐药结核分枝杆菌感染动物模型所用菌株。收集从我国部分省份98例结核病患者痰培养液中分离出的结核分枝杆菌,用比例法药敏试验进行结核分枝杆菌一线和二线药物的药敏试验,筛选出对二线药物敏感而对一线药物利福平或异烟肼耐药或敏感的菌株,然后进行小鼠体内毒力实验,对异烟肼耐药相关基因katG和利福平耐药相关基因rpoB测序并进行基因突变分析。从98株菌中筛选出药物敏感谱清晰的40株,进行小鼠体内毒力实验。结果显示,共35株半数死亡时间≤H37Rv的半数死亡时间,其中18株耐利福平合并耐异烟肼、5株单耐利福平,7株单耐异烟肼、5株对利福平和异烟肼均敏感。通过小鼠毒力研究,分别筛选出基因背景清晰,半数死亡时间≤7d的耐利福平合并耐异烟肼的菌株1株、半数死亡时间≤7d单耐利福平和异烟肼的菌株各1株,作为耐药结核分枝杆菌感染小鼠模型所用菌株及进一步进行豚鼠等其他动物模型感染用候选菌株。     

治疗性结核病疫苗研究进展

治疗性结核病疫苗主要用于接种已感染结核分枝杆菌的个体,包括化学药物治疗的患者和潜伏感染者。治疗性疫苗可逆转发生在疾病进展期的非保护性免疫反应,使其向Th1型反应发展;能打破机体的免疫耐受,有效激发宿主针对结核分枝杆菌的以抗原为基础的细胞免疫反应,诱发抗原特异性的细胞毒性T淋巴细胞免疫反应,来清除胞内寄生的结核分枝杆菌。治疗性疫苗将有助于防止潜伏结核病的复发;与药物联合使用以提高药物的治疗效果,尤其是针对耐药结核病的治疗。     

耐药结核分枝杆菌基因组信息挖掘

<正>由于结核分枝杆菌的耐药性问题,使结核病这个古老的传染病死灰复燃,并成为全球性的严重公关问题。从1998年首个结核分枝杆菌(H37Rv)全基因组完成图的获得[1],到近年来采用新一代测序技术对多个菌株进行高通量的基因组测序与分析,对结核分枝杆菌进化及耐药机制的认识不断深入。关于结核分枝杆菌菌株的基因组比较分析有多篇报道,包括对中国12个省来源的161株结核分枝杆菌     

结核分枝杆菌Rv1057基因对巨噬细胞感染早期细胞因子表达的影响分析

Rv1057是结核分枝杆菌中唯一的7-折叠片β-螺旋蛋白,其生物学功能尚不清楚。为探讨Rv1057基因在结核分枝杆菌感染初期对巨噬细胞免疫应答的影响,利用Rv1057基因缺失菌株D1057和野生型H37Rv菌株感染巨噬细胞,检测结核分枝杆菌在巨噬细胞内的增殖速度,分析巨噬细胞在感染初期的细胞因子表达量变化。研究结果表明:D1057菌株在巨噬细胞内的活菌数量和增殖速度都显著低于H37Rv,被D1057感染的巨噬细胞中IL-1β、IL-10、TNF-α和IFN-γ表达量显著降低,但IL-8大量表达且无显著差异。上述研究结果证实,缺失Rv1057会降低结核分枝杆菌刺激巨噬细胞产生某些细胞因子的能力,明确了Rv1057基因参与结核分枝杆菌与巨噬细胞之间的免疫应答,为进一步解析Rv1057基因的生物学功能、结核分枝杆菌的致病机制奠定了基础。     

结核分枝杆菌潜伏性感染发生机制的研究进展

结核分枝杆菌是结核病的致病菌,随着全球结核病的再次蔓延及艾滋病的流行,结核分枝杆菌的潜伏性感染日益到重视,本文就该菌潜伏感染动物模型的建立,潜伏性感染中该菌的生物学特性以及潜伏性感染的免疫发病机制等方面的研究进展一综述。     

结核杆菌潜伏感染小鼠模型的制备及其评价指标

目前对于结核分枝杆菌进入潜伏期的机制以及再激化的原因知之甚少,一个重要的原因是缺乏潜伏感染(LTBI)动物模型,完整的LTBI模型应包括两种类型,一是低剂量荷菌的持续性感染模型,另一种为潜伏感染模型,即Cornell模型的改进型。综合使用柯氏量表评分、脾肺荷菌数、诱导的IFN-γ和TNF-α水平、组织中IL-10和IL-4的表达、脏器中特异性抗原负荷以及激素诱导TB复发的时间、潜伏感染相关基因的表达水平等指标可以比较准确、客观、特异性的评价小鼠LTBI模型的反应性。     

检测不同毒力结核分枝杆菌感染对巨噬细胞凋亡的影响及其Caspase-3和Bcl-2的表达

该文为探讨不同毒力的结核分枝杆菌感染对巨噬细胞凋亡的调控作用及其机制。实验用结核分枝杆菌国际标准强毒株H37Rv株和卡介苗BCG分别感染巨噬细胞RAW264.7株,同时设空白对照组,在感染后1,6,12,24 h,用流式细胞技术检测各组巨噬细胞的凋亡率,应用Western blot检测细胞Caspase-3和Bcl-2蛋白表达。结果发现,结核分枝杆菌感染组的凋亡率显著高于对照组,差异具有统计学意义(P<0.05);BCG感染组凋亡率高于H37Rv感染组,在感染后1,12,24 h凋亡率显著升高,差异具有统计学意义(P<0.05)。巨噬细胞感染结核分枝杆菌后其Caspase-3蛋白表达增高,结核分枝杆菌感染组的Caspase-3蛋白表达高于对照组:对照组相似文献   

结核分枝杆菌毒素-抗毒素系统与生物膜

结核分枝杆菌(Mycobacterium tuberculosis)是引起结核病的病原菌。其处于持续生存的休眠状态时,可导致长期无症状感染,称为结核潜伏感染。研究显示,结核分枝杆菌染色体中存在大量 “毒素-抗毒素系统”(toxin-antitoxin system,TAS),某些TAS在潜伏感染中发挥作用,可调节细菌生长和诱导细菌进入休眠状态;某些TAS参与生物膜形成和应激反应,但其影响生物膜形成的机制尚未阐明。生物膜中的结核分枝杆菌对多种抗结核药物耐药,且能抵抗宿主免疫系统防御;休眠状态的结核分枝杆菌对抗结核药物通常也是耐受的,给结核病治疗带来了巨大挑战。本文就近年来结核分枝杆菌TAS与生物膜的研究及抗结核药物对生物膜形成的影响进行综述。     

IL-22基因多态性与中国人群肺结核易感性的相关性研究

本研究旨在探讨白细胞介素22(interleukin 22,IL-22)基因多态性位点与肺结核易感性的关系。采用SNPscan™多重单核苷酸多态性(single nucleotide polymorphism,SNP)分型技术,对453例肺结核患者(结核病组)和373例与患者长期密切接触者〔包括109例潜伏结核感染(latent tuberculosis infection,LTBI)者、264例健康对照者〕的IL-22基因的4个SNP位点(rs1179249、rs2227491、rs17224704、rs2227478)多态性进行分析。结核病组、LTBI组和对照组中4个SNP位点的基因型分布经哈温平衡(Hardy-Weinberg equilibrium,HWE)检验均处于遗传平衡状态。结果显示,rs17224704位点存在AA、TA和TT基因型。＞55岁人群中,此位点TA基因型在对照组中的分布显著高于结核病组(P＝0.047 9,OR＝0.365,95% CI＝0.135～0.991);AA基因型在LTBI组中的分布显著低于结核病组(P＝0.027 6);TA基因型在LTBI组中的分布显著高于结核病组(P＝0.007 37,OR＝0.213,95% CI＝0.069～0.660)。对照组和LTBI组的等位基因T频率显著高于结核病组(P＝0.026 9,OR＝0.388,95% CI＝0.167～0.897;P＝0.025 0,OR＝0.322,95% CI＝0.119～0.867)。IL-22基因rs17224704的多态性可能与中国重庆地区汉族人群肺结核易感性显著相关,其等位基因T可能是肺结核的保护基因。     

结核分枝杆菌潜伏感染诊断方法的新进展

每年有超过8百万人感染结核,其中绝大部分没有发展为活动性结核病,而是表现为潜伏性结核感染。大多数活动性结核病是潜伏感染的结核杆菌重新被激活所致,因此结核潜伏感染者成为结核患者的重要来源。及早诊断和治疗结核潜伏感染者是控制结核传播的最有效手段之一。我们较要综述了目前国内外结核潜伏感染的诊断方法及其新进展。     

Identification of promising plasma immune biomarkers to differentiate active pulmonary tuberculosis

Although much research has been done related to biomarker discovery for tuberculosis infection, a set of biomarkers that can discriminate between active and latent TB diseases remains elusive. In the current study we correlate clinical aspects of TB disease with changes in the immune response as determined by biomarkers detected in plasma. Our study measured 18 molecules in human plasma in 17 patients with active disease (APTB), 14 individuals with latent tuberculosis infection (LTBI) and 16 uninfected controls (CTRL). We found that active tuberculosis patients have increased plasma levels of IL-6, IP-10, TNF-α, sCD163 and sCD14. Statistical analysis of these biomarkers indicated that simultaneous measurement of sCD14 and IL-6 was able to diagnose active tuberculosis infection with 83% accuracy. We also demonstrated that TNF-α and sCD163 were correlated with tuberculosis severity. We showed that the simultaneous detection of both plasma sCD14 and IL-6 is a promising diagnostic approach to identify APTB, and further, measurement of TNF-α and sCD163 can identify the most severe cases of tuberculosis.     

Novel serological biomarker panel using protein microarray can distinguish active TB from latent TB infection

BackgroundRapid laboratory technologies which can effectively distinguish active tuberculosis (ATB) from controls and latent tuberculosis infection (LTBI) are lacked.The objective of this study is to explore MTB biomarkers in serum that can distinguish ATB from LTBI.MethodsWe constructed a tuberculosis protein microarray containing 64 MTB associated antigens. We then used this microarray to screen 180 serum samples, from patients with ATB and LTBI, and healthy volunteer controls. Both SAM (Significance analysis of microarrays) and ROC curve analysis were used to identify the differentially recognized biomarkers between groups. Extra 300 serum samples from patients with ATB and LTBI, and healthy volunteer controls were employed to validate the identified biomarkers using ELISA-based method.ResultsAccording to the results, the best biomarker combinations of 4 proteins (Rv1860, RV3881c, Rv2031c and Rv3803c) were selected. The biomarker panel containing these 4 proteins has reached a sensitivity of 93.3% and specificity of 97.7% for distinguishing ATB from LTBI, and a sensitivity of 86% and specificity of 97.6% for distinguishing ATB from HC.ConclusionThe biomarker combination in this study has high sensitivity and specificity in distinguishing ATB from LTBI, suggesting it is worthy for further validation in more clinical samples.     

Secretory proteins of Mycobacterium habana induce a protective immune response against experimental tuberculosis

The capacity of proteins of Mycobacterium habana TMC 5135 secreted into culture medium during the mid-exponential growth phase (secretory proteins, SPs) to induce protective immunity against Mycobacterium tuberculosis H37Rv was studied in the mouse model. Mice immunized with SPs followed by a challenge with M. tuberculosis H37Rv showed lesser M. tuberculosis bacilli in their lung and spleen and survived longer than unimmunized controls. The findings suggest that SP antigens of M. habana are protective against tuberculosis infection.     

The non-human primate model of tuberculosis

Non-human primates (NHPs) are used to model human disease owing to their remarkably similar genomes, physiology, and immune systems. Recently, there has been an increased interest in modeling tuberculosis (TB) in NHPs. Macaques are susceptible to infection with different strains of Mycobacterium tuberculosis (Mtb), producing the full spectrum of disease conditions, including latent infection, chronic progressive infection, and acute TB, depending on the route and dose of infection. Clearly, NHPs are an excellent model of human TB. While the initial aim of the NHP model was to allow preclinical testing of candidate vaccines and drugs, it is now also being used to study pathogenesis and immune correlates of protection. Recent advances in this field are discussed in this review. Key questions such as the effect of hypoxia on the biology of Mtb and the basis of reactivation of latent TB can now be investigated through the use of this model.     

Serum antibody profiles in individuals with latent Mycobacterium tuberculosis infection

One‐third of the world's humans has latent tuberculosis infection (LTBI), representing a large pool of potentially active TB. Recent LTBI carries a higher risk of disease progression than remote LTBI. Recent studies suggest important roles of antibodies in TB pathology, prompting us to investigate serum antibody profiles in a cohort with LTBI. In this single‐center prospective observational study, we analyzed IgG‐antibody concentrations against five major Mycobacterium tuberculosis (Mtb) antigens (including 6 kDa early secretory antigenic target (ESAT6), CFP10, and antigen 85A, which are expressed mainly in the growth phase; and mycobacterial DNA‐binding protein 1 (MDP1) and alpha‐crystallin like protein (Acr), which are expressed in the dormant phases) in individuals with recent (n=13) or remote (n=12) LTBI, no Mtb infection (n=19), or active TB (n=15). Antibody titers against ESAT6 and MDP1 were significantly higher in individuals with recent LTBI than in those with no Mtb infection or remote LTBI. All pairwise antibody titers against these five major antigens were significantly correlated throughout the stages of Mtb infection. Five individuals with recent LTBI had significantly higher antibody titers against ESAT6 (P = 0.03), Ag85A (P = 0.048), Acr (P = 0.057), and MDP1 (P = 0.0001) than in individuals with remote LTBI; they were also outside the normal range (+2 SDs). One of these individuals was diagnosed with active pulmonary TB at 18‐month follow‐up examination. These findings indicated that concentrations of antibodies against both multiplying and dormant Mtb are higher in recent LTBI and that individuals with markedly higher antibody titers may be appropriate candidates for prophylactic therapy.